title: Therapeutic effects of a combinatorial treatment of simvastatin and bone marrow stromal cells on experimental embolic stroke.
abstract: In this study, we investigated the therapeutic effects of simvastatin administered in combination with bone marrow stromal cells (BMSCs) following experimentally induced embolic stroke in rats. Effects on infarct volume, brain oedema and neurological deficits were examined. Focal ischaemic brain injury was induced by emblazing a preformed clot into the middle cerebral artery in rats. Animals were administered simvastatin (40 mg/kg) at 1 hr after stroke, or BMSCs (3 × 10(6)) at 24 hr after stroke or a combination of these two treatments. Rats receiving a dose of simvastatin in combination with BMSC administration demonstrated a significant reduction in neurological deficits, a significant reduction in infarct volume and a significant decrease in brain oedema. Our data show that combining simvastatin administration with BMSCs has an additive effect on improving functional outcome in this thromboembolic stroke model.
authors.affiliation: Department of Physiology & Electrophysiology Research Centre, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: G
authors.initials: G
authors.lastname: Pirzad Jahromi
authors.forename: S
authors.initials: S
authors.lastname: Seidi
authors.forename: S S
authors.initials: SS
authors.lastname: Sadr
authors.forename: A P
authors.initials: AP
authors.lastname: Shabanzadeh
authors.forename: M
authors.initials: M
authors.lastname: Keshavarz
authors.forename: G R
authors.initials: GR
authors.lastname: Kaka
authors.forename: S K
authors.initials: SK
authors.lastname: Hosseini
authors.forename: H
authors.initials: H
authors.lastname: Sohanaki
authors.forename: J
authors.initials: J
authors.lastname: Charish
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D015415:Biomarkers / Q000032:analysis; D016026:Bone Marrow Transplantation; D001929:Brain Edema / Q000209:etiology / Q000517:prevention & control; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D005353:Fibronectins / Q000032:analysis; D018960:Hyaluronan Receptors / Q000032:analysis; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D020244:Infarction, Middle Cerebral Artery / Q000150:complications / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D017493:Leukocyte Common Antigens / Q000032:analysis; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D020127:Recovery of Function; D019821:Simvastatin / Q000494:pharmacology*; D020521:Stroke / Q000209:etiology / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D017154:Stromal Cells / Q000737:chemistry / Q000637:transplantation*; D013997:Time Factors
chemical_list: D015415:Biomarkers; D005353:Fibronectins; D018960:Hyaluronan Receptors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019821:Simvastatin; D017493:Leukocyte Common Antigens; C516771:Ptprc protein, rat